Christoph U. Correll, MD, PhD
a:3:{i:0;s:116:"Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Uniondale, New York";i:1;s:71:"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York";i:2;s:93:"Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany";}
Original Research
Long-Term Remission With Cariprazine in Patients With Schizophrenia
January 8, 2019
When treating patients with schizophrenia, achieving stable, long-term remission is an important step toward the goal of functional recovery. This study evaluated the effect of cariprazine on several measures...
Original Research
Valbenazine for Tardive Dyskinesia: Results From the KINECT 3 Study
December 18, 2018
Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
Educational Activity
Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
February 21, 2018
Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify...
